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CUTANEOUS MICROVASCULATURE OF HUMAN CHRONIC GVHD LACKS
THE VASCULAR RAREFACTION OR THE ABNORMAL ENDOTHELIAL
CELL PHENOTYPE OF SYSTEMIC SCLEROSIS
Fleming, J.N.1, Shulman, H.M.2, Schwartz, S.M.1 1University of Wash-
ington, Seattle, WA; 2Fred Hutchinson Cancer Research Center, Seattle,
WA
Background: Though endstage human cutaneous c-GVHD and
systemic sclerosis (SSc) appear histologically similar, structural
changes of small vessels in the superficial dermal microvasculature
(SDM)and dermis of affected skin have not been comprehensively
compared. We addressed the question: does c-GVHD have micro-
vascular alterations similar to those in SSc making it a suitable path-
ogenetic model for SSc?
Methods: We analyzed skin biopsies from 30 SSc and 13 c-
GVHD both with a range of dermal fibrosis scores (DFS) Blood
2007:110,1388, and 24 normal controls. DFS was based on H&E
stained collagen and dermal matrix changes in full thickness skin bi-
opsies. Immunostaining of SDM with physiologic endothelial (ED)
Ab’s to vWF,CD31, and VECadherin (VEC) were used for defining
ED phenotype and vessel quantification. Ab’s for smooth muscle ac-
tin, smooth muscle myosin heavy chain and hyaluronan were also
used to identify formation of intima and highlight vascular wall
smooth muscle changes.
Results: In c-GVHD the dermal fibrosis typically progressed in
a top down progression whereas in SSc it was a bottom up pattern.
The pansclerotic endstage of both conditions had similar dermalma-
trix composition and smooth muscle pathology (including intimal
hyperplasia) significantly different from normals. C-GVHD signifi-
cantly differed fromSSC in several ways: 1. Average vessel count in c-
GVHD 16.5 vs 9.8 Scc (p5\0.0001), 2. In addition, c-GVHD had
no loss of the important canonical EDmarkers VEC and vWF, both
0/13 whereas both VEC and vWF were decreased compared with
CD31 expression (19/19 and 12/14 respectively) in SSc (p 5 \
0.0001 and\0.05), respectively). 3. Lastly, c-GVHD had areas of
microvascular ED proliferation absent in the SSc biopsies.
Conclusion: C-GVHD shares some histologic features with SSc
but the progression of the dermal fibrosis appears different. The
ED markers in c-GVHD remain constant, whereas in contrast, in
SSc an intrinsically abnormal anti-angiogenic ED cell phenotype
with loss of the canonical ED markers vWF and VEC may be re-
lated to the microvascular rarefaction and lack of angiogenesis.
PloS One 2008:3: e1452 VEC in particular is required for the for-
mation of endothelial tubes in vitro and in vivo, and loss of its ex-
pression in SSc may contribute to the loss of capillaries in SSc skin.
C-GVHD is a suitable model for studying dermal sclerosis, but
probably not suitable for studying the microvascular changes in
Scc.88
INCIDENCE OF CMV INFECTION IN AUTOIMMUNE DISEASES AFTER AU-
TOLOGOUS STEM CELL TRANSPLANTATION
Pieroni, F.1, Stracieri, A.B.P.1, Oliveira, M.C.B.1, Morais, D.A.1,
Barros, G.M.1, Madeira, M.I.A.1, Simoes, B.P.2, Voltarelli, J.C.2 1Clin-
ical Hospital of the School of Medicine of Ribeira˜o Preto of the University of
Sa˜o Paulo, Ribeira˜o Preto, Sa˜o Paulo, Brazil; 2School of Medicine of
Ribeira˜o Preto of the University of Sa˜o Paulo, Ribeira˜o Preto, Sa˜o Paulo,
Brazil
Autoimmune diseases have been successfully treated with high-
dose immunosuppression followed by ASCT. There is no report re-
garding the incidence of CMV infection in this subset of patients.
We report here the incidence of CMV infection in 88 consecutive
ASCT for autoimune disease. Table 1 shows patients characteristics.
Before ASCT, all patients were seropositive for CMV. The used36conditioning regimens were BEAM 1 hATG 30mg/Kg for 11 MS
patients, and Cy 200mg/Kg 1 rATG 4,5mg/Kg for the other pa-
tients. All patients received peripheral blood as the source of stem
cells. Blood red cells and platelets infused were all irradiated and fil-
trated. The blood CMV pp65 antigen test was based on the mono-
clonal antibody against the virus and immunofluorescence. CMV
infection was defined as a positivity of at least one pp65 antigenemia
assay at any level. A CMVpp65 antigenemia assay was determined
weekly, starting from the day when the absolute neutrophil count
went above 500  103/ul, and until day 60 after ASCT. Patients
with five or more positive CMV cells, in use of corticosteroids
with any number of positive CMV cells and with any clinical signs
of CMV disease with any number of positive CMV cells were treated
with Gancyclovir. Among the 88 transplanted patients, 20,5% pre-
sented a positive antigenemia. The first positive antigenemia pre-
sented a median of 19 days after stem cell reinfusion (range 05 to
52). The median antigenemia level at the first appearance was 2 in-
fected cells (range 1–40). Overall, 07 patients were treated with Gan-
cyclovir. Five were treated preemptively. Two patients had CMV
pneumonits, and one died from it. In 61% of the cases, CMV reac-
tivation was asymptomatic with less them 5 cells positive and antige-
nemia has cleared spontaneously. Our study shows that CMV
infection can reactivate in a significant proportion of seropositive pa-
tients after ASCT. However, despite the use of Antimocyte Globu-
lin, the rate of CMV reactivation in this subset of patients seens
not be different from the rate of reactivation recently encountered af-
ter ASCT for hematologic malignancies (Rossini, F., et al, Transpl
Infect Dis 2005: 7: 122–125). Moreover, in spite of the fact that
CMV infection was asymptomatic and antigenemia clears spontane-
ously in a proportion of the cases, if we consider the severity of CMV
disease, its high rate of mortality, and the high costs of treating it, we
think that these results can justify surveillance in seropositive pa-
tients.
Table 1Patients characteristicsTransplanted patients 88
Median age 34 (13-55)
Female/Male ratio 3:1
Autoimmune disease Number of patients
Multiple Sclerosis 45
Type 1 Diabetes Mellitus 22
Systemic Sclerosis 09
Systemic Lupus Eritematous 04
Neuromyelitis Optica 04
Amyotrophic Lateral Sclerosis 02
Vulgar Pemphigus 01
Takayasu Arteritis 01AUTOLOGOUS TRANSPLANTS
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COMPARISON OF CLINICAL OUTCOMES OF RELAPSED APL PATIENTS
INDUCED WITH ATO AND CONSOLIDATED WITH EITHER AN AUTOLO-
GOUS SCT OR ATO BASED TREATMENT REGIMEN
Mathews, V., George, B., Lakshmi, K.M., Chendamarai, E.,
Viswabandya, A., Srivastava, A., Chandy, M. Christian Medical College,
Vellore, Tamil Nadu, India
Arsenic trioxide (ATO) is the most effective agent in inducing
remission among patients with relapsed acute promyelocytic
leukemia (APL). After induction of remission in relapsed patients
with ATO the best consolidation regimen remains to be defined.
Since January 2000, 37 patients with relapsed APL were treated
at our center. The median age was 34 years (range: 6 – 57) and
there were 20 (54.1%) males. The initial treatment was conven-
tional ATRA plus chemotherapy in 23 (62.2%) and single agent
ATO in 14 (37.8%). The median duration of first remission was
